Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Menopause
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Menopause
    TopAbstracts in Menopause 11/24/2009 - (DGNews)
    TopAbstracts in Menopause 11/10/2009 - (DGNews)
    TopAbstracts in Menopause 10/27/2009 - (DGNews)
    TopAbstracts in Menopause 10/13/2009 - (DGNews)
    Novel Administration Method for Hormone Therapy May Offer Increased Safety, Other Benefits: Presented at NAMS - (DGDispatch)

    News archive

     Recent webcasts/CME - Menopause
      Issues in Postmenopausal Hormone Therapy
      The Council on Menopause Management Video: Clinical Challenges and Quality of Life Issues
      How to Appropriately Counsel and Manage a Recently Menopausal Woman Worried About the Safety of Hormone Therapy
      Endocrinology and Management of Hormone Therapy in Older Women
      Endocrinology and Management of Hormone Therapy in Older Women

      Webcasts/CME archive

       Recent cases - Menopause
        Giant Ovarian Serous Cystadenoma in a Postmenopausal Woman: A Case Report
        Spontaneous Perforated Pyometra with an Intrauterine Device in Menopause: a Case Report
        Female Sexual Dysfunction
        Female Sexual Dysfunction: Does Surgically Induced Menopause Matter?
        A Postmenopausal Woman Presenting with Atypical Symptoms and Cervical Cancer : A Case Report

        Cases archive
          




        my personal edition > menopause > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Promensil, Rimostil, And Placebo Result In Similar Reductions In Hot Flashes Frequency

        Journal of the American Medical Association (JAMA)

        07/09/2003
        By Joene Hendry


        Promensil and Rimostil, both isoflavone extracts derived from red clover, or placebo showed similar reductions in hot flash frequency over 12 weeks of treatment according to the findings of The Isoflavone Clover Extract Study.

        Jeffrey A. Tice, MD, of the University of California, San Francisco, United States and colleagues randomised 252 women to twice daily Promensil (82 mg total isoflavone per day), Rimostil (57 mg total isoflavone per day), or placebo to measure and changes in hot flash frequency. All women, 45 to 60 years of age, were menopausal (follicle- stimulating hormone levels of 30 mIU/mL) and reported at least 35 hot flashes per week.

        The mean reduction in hot flash count after 12 weeks was 41% in the Promensil group (n=84), 34% of the Rimostil group (n=83), and 36% for the placebo group (n=85). While the change in hot flash counts over the study period was significant for all 3 groups the reduction in hot flash counts in the Promensil and the Rimostil groups were not statistically different from placebo.

        Promensil, but not Rimostil, reduced the frequency of hot flashes more rapidly than placebo but women in all 3 groups were still experiencing more than 5 hot flashes per day at the end of the study.

        Reductions in hot flash frequency were most pronounced for women above the median body mass index (BMI) of 25.1, but the researchers note that it is unclear why phytoestrogens would have a greater efficacy in this group. The reduction in hot flashes was 49% for women over the median BMI compared with 30% for women under the median BMI who were taking Promensil. In the Rimostil group, those over the median BMI had a 45% reduction compared with a 22% reduction in hot flashes for women below the median BMI. Conversely, women in the placebo group over the median BMI reported a 32% reduction in hot flashes while women under the median BMI showed a 40% reduction.

        Adverse events, including headache and vaginal spotting, were reported in at least 3% of the study participants but there was no statistically significant association between adverse events and either of the phytoestrogen supplements.

        The researchers conclude that while this study provides some evidence for a biological effect of Promensil, "neither supplement had a clinically significant effect on hot flashes or other menopausal symptoms when compared with placebo."
        JAMA 2003;290:2:207-214.

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send